U-Neuron Biomedical (ROCO:6973) EBIT : NT$-84.84 Mil (TTM As of Dec. 2023)

View and export this data going back to 2023. Start your Free Trial

What is U-Neuron Biomedical EBIT?

U-Neuron Biomedical's earnings before interest and taxes (EBIT) for the six months ended in Dec. 2023 was NT$-28.80 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Dec. 2023 was NT$-84.84 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. U-Neuron Biomedical's annualized ROC % for the quarter that ended in Dec. 2023 was -211.44%. U-Neuron Biomedical's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was -537.02%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. U-Neuron Biomedical's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was -9.23%.

U-Neuron Biomedical EBIT Historical Data

The historical data trend for U-Neuron Biomedical's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

U-Neuron Biomedical EBIT Chart

U-Neuron Biomedical Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

EBIT

-11.26

-43.06

-84.84

U-Neuron Biomedical Semi-Annual Data
	Dec21	Jun22	Dec22	Jun23	Dec23
EBIT	-	-16.95	-26.11	-56.04	-28.80

Competitive Comparison of U-Neuron Biomedical's EBIT

For the Biotechnology subindustry, U-Neuron Biomedical's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

U-Neuron Biomedical's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, U-Neuron Biomedical's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where U-Neuron Biomedical's EV-to-EBIT falls into.

U-Neuron Biomedical EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was NT$-84.84 Mil.

U-Neuron Biomedical (ROCO:6973) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

U-Neuron Biomedical's annualized ROC % for the quarter that ended in Dec. 2023 is calculated as:

	ROC % (Q: Dec. 2023 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Jun. 2023 )	+	Invested Capital (Q: Dec. 2023 ))	/ count )
=	-65.102 * ( 1 - 0% )	/	( (17.599	+	43.98)	/ 2 )
=	-65.102	/	30.7895
=	-211.44 %

where

	Invested Capital		(Q: Jun. 2023 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	539.491	-	8.903	-	( 515.125	-	max(0, 16.671	-	529.66	+	515.125	))
=	17.599

	Invested Capital		(Q: Dec. 2023 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	523.169	-	14.988	-	( 475.957	-	max(0, 25.665	-	489.866	+	475.957	))
=	43.98

Note: The Operating Income data used here is two times the semi-annual (Dec. 2023) data.

2. Joel Greenblatt's definition of Return on Capital:

U-Neuron Biomedical's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2023 is calculated as:

	ROC (Joel Greenblatt) %		(Q: Dec. 2023 )
=	EBIT	/	Average of (Net fixed Assets	+	Net Working Capital)
=	EBIT	/	Average of (Property, Plant and Equipment	+	Net Working Capital)
			Q: Jun. 2023		Q: Dec. 2023
=	EBIT	/	( ( (Property, Plant and Equipment + Net Working Capital)	+	(Property, Plant and Equipment + Net Working Capital) )	/	count )
=	-57.59	/	( ( (6.357 + max(-0.23499999999999, 0))	+	(15.091 + max(-7.259, 0)) )	/	2 )
=	-57.59	/	( ( 6.357	+	15.091 )	/	2 )
=	-57.59	/	10.724
=	-537.02 %

where Working Capital is:

	Working Capital		(Q: Jun. 2023 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(2.421	+	9.18	+	2.634)	-	(8.903	+	0	+	5.567)
=	-0.23499999999999

	Working Capital		(Q: Dec. 2023 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(2.109	+	8.821	+	2.709)	-	(14.988	+	0	+	5.91)
=	-7.259

When net working capital is negative, 0 is used.

Note: The EBIT data used here is two times the semi-annual (Dec. 2023) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

U-Neuron Biomedical's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %	=	EBIT (TTM)	/	Enterprise Value (Q: Dec. 2023 )
	=	-84.836	/	919.601
	=	-9.23 %

U-Neuron Biomedical EBIT Related Terms

Thank you for viewing the detailed overview of U-Neuron Biomedical's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

U-Neuron Biomedical (ROCO:6973) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » U-Neuron Biomedical Inc (ROCO:6973) » Definitions » EBIT

Comparable Companies

Traded in Other Exchanges

N/A

Address

Website

https://en.u-neuron.com

U-Neuron Biomedical Inc is engaged in research and development of stem cell storage & separation technology, and treatment application technology. It has patent on the Technology of Culture and Isolation of Amniotic Fluid Stem Cell.

U-Neuron Biomedical (ROCO:6973) Headlines

No Headlines